Academic Journal
The effects of gonadal hormones on heroin Self-Administration in male gonadectomized rats.
| Τίτλος: | The effects of gonadal hormones on heroin Self-Administration in male gonadectomized rats. |
|---|---|
| Συγγραφείς: | Smith MA; Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA. masmith@davidson.edu., Pearson T; Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA., Ballard SL; Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA., Camp JD; Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA., Sharp JL; Department of Psychology and Program in Neuroscience, Davidson College, Davidson, NC, USA. |
| Πηγή: | Psychopharmacology [Psychopharmacology (Berl)] 2024 Jan; Vol. 241 (1), pp. 171-179. Date of Electronic Publication: 2023 Oct 13. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Berlin, New York, Springer-Verlag. |
| Ιατρικοί όροι (MeSH): | Heroin*/pharmacology , Progesterone*/pharmacology, Estradiol/pharmacology ; Testosterone/pharmacology ; Humans ; Rats ; Male ; Female ; Animals ; Rats, Sprague-Dawley ; Reinforcement Schedule ; Self Administration |
| Περίληψη: | Rationale: Previous studies have shown that gonadal hormones influence opioid self-administration in female rodents, but very few studies have examined these effects in male rodents. Objectives: The purpose of this study was to examine the effects of chronic hormone treatment on intravenous heroin self-administration in gonadectomized male rats using both physiological and supraphysiological doses of testosterone, estradiol, or progesterone. Methods: Gonadectomized male rats were surgically implanted with intravenous catheters and trained to self-administer heroin on a fixed ratio (FR1) schedule of reinforcement. Using a between-subjects design, rats were treated daily with testosterone (0.175 or 1.75 mg, sc), estradiol (0.0005 or 0.005 mg, sc), progesterone, (0.0125 or 0.125 mg, sc), or their vehicles. After 14 days of chronic treatment, a dose-effect curve was determined for heroin (0.0003-0.03 mg/kg/infusion) over the course of one week. Results: Neither testosterone nor estradiol altered responding maintained by heroin. In contrast, the high dose of progesterone (0.125 mg) reduced responding maintained by all doses of heroin to saline-control levels. This dose of progesterone did not reduce responding maintained by food on a progressive ratio schedule in either food-restricted or food-sated rats. Conclusions: These data indicate that exogenous progesterone or a pharmacologically active metabolite selectively decreases heroin intake in male rodents, which may have therapeutic implications for men with opioid use disorder. (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Steroids. 2011 Nov;76(12):1310-6. (PMID: 21745486) Front Psychiatry. 2015 Jul 06;6:91. (PMID: 26217239) Neuropsychopharmacology. 2004 Jan;29(1):81-5. (PMID: 12955098) Exp Aging Res. 1981 Spring;7(1):25-32. (PMID: 7238548) J Endocrinol. 1973 May;57(2):277-84. (PMID: 4706601) Arch Gen Psychiatry. 1989 Feb;46(2):122-6. (PMID: 2913971) Drug Alcohol Depend. 2007 Jul 10;89(2-3):183-9. (PMID: 17240083) Neurosci Lett. 2007 Nov 20;428(1):33-7. (PMID: 17945420) Endocrinology. 1977 Dec;101(6):1821-7. (PMID: 338291) Neuroreport. 2014 May 7;25(7):521-6. (PMID: 24488032) Mol Neurobiol. 2017 May;54(4):2611-2621. (PMID: 26993300) Physiol Behav. 2002 Aug;76(4-5):605-9. (PMID: 12126999) Pharmacol Biochem Behav. 1991 Aug;39(4):923-7. (PMID: 1763112) Pharmacol Biochem Behav. 2003 Feb;74(3):541-9. (PMID: 12543217) J Endocrinol. 1974 Mar;60(3):409-19. (PMID: 4823249) J Neurosci. 2003 Jan 15;23(2):693-9. (PMID: 12533629) Brain Res. 2002 Jul 26;945(1):123-30. (PMID: 12113959) Drug Alcohol Depend. 2020 Jan 1;206:107733. (PMID: 31790978) Behav Brain Res. 2021 Jul 9;409:113329. (PMID: 33933523) Exp Clin Psychopharmacol. 2022 Apr;30(2):127-131. (PMID: 33001695) Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-200-4. (PMID: 18646349) Physiol Behav. 1988;44(2):257-65. (PMID: 3237832) Neuropsychopharmacology. 2001 Jul;25(1):118-30. (PMID: 11377925) Neurosci Lett. 2009 Oct 25;462(3):289-93. (PMID: 19595744) Psychopharmacology (Berl). 2015 Oct;232(20):3773-82. (PMID: 26246318) Physiol Behav. 2011 Jan 10;102(1):96-104. (PMID: 20932851) Horm Behav. 1992 Dec;26(4):457-73. (PMID: 1335955) Psychoneuroendocrinology. 2001 Nov;26(8):789-96. (PMID: 11585679) Pharmacol Biochem Behav. 2005 Sep;82(1):98-108. (PMID: 16111740) Neuroendocrinology. 2023;113(11):1099-1111. (PMID: 36878201) Psychopharmacology (Berl). 2000 Feb;148(2):196-200. (PMID: 10663435) Learn Mem. 2019 Dec 16;27(1):6-11. (PMID: 31843977) Neuropsychopharmacology. 2004 May;29(5):929-42. (PMID: 14735136) Behav Brain Res. 1999 Jul;102(1-2):89-98. (PMID: 10403018) Psychoneuroendocrinology. 2009 Apr;34(3):343-52. (PMID: 18977603) J Subst Abuse Treat. 1993 Jan-Feb;10(1):63-6. (PMID: 8450576) Exp Clin Psychopharmacol. 2007 Oct;15(5):472-80. (PMID: 17924781) Addict Biol. 2020 Nov;25(6):e12822. (PMID: 31830773) Psychopharmacology (Berl). 2021 Apr;238(4):969-978. (PMID: 33404736) Br J Pharmacol. 2023 Apr;180(7):910-926. (PMID: 34986504) Pharmacol Ther. 2015 Sep;153:55-78. (PMID: 26049025) Neuropsychopharmacology. 2006 Jan;31(1):129-38. (PMID: 15920500) Behav Brain Res. 2007 Dec 3;184(2):174-84. (PMID: 17707520) Psychopharmacology (Berl). 2016 Sep;233(17):3201-10. (PMID: 27370020) Exp Clin Psychopharmacol. 2023 Apr;31(2):362-369. (PMID: 35587421) Drug Alcohol Depend. 2010 Mar 1;107(2-3):264-7. (PMID: 20005642) Scand J Clin Lab Invest. 2005;65(8):699-705. (PMID: 16319044) Horm Behav. 1993 Dec;27(4):568-83. (PMID: 8294123) Psychopharmacology (Berl). 1989;98(3):408-11. (PMID: 2501818) Arch Physiol Biochem. 2003 Dec;111(5):429-36. (PMID: 16026030) Horm Metab Res. 2014 Mar;46(3):211-8. (PMID: 24446162) Neurosci Biobehav Rev. 2022 Mar;134:104522. (PMID: 34995646) Neuropsychopharmacology. 2011 Oct;36(11):2187-99. (PMID: 21796112) Horm Behav. 2001 Nov;40(3):409-18. (PMID: 11673914) Pharmacol Biochem Behav. 2013 Mar;104:40-6. (PMID: 23305678) |
| Grant Information: | R01 DA031725 United States DA NIDA NIH HHS; R01 DA045364 United States DA NIDA NIH HHS; DA031725 United States NH NIH HHS; DA045364 United States NH NIH HHS |
| Contributed Indexing: | Keywords: Estradiol; Opioid; Opioid use disorder; Progesterone; Testosterone |
| Substance Nomenclature: | 70D95007SX (Heroin) 4G7DS2Q64Y (Progesterone) 4TI98Z838E (Estradiol) 3XMK78S47O (Testosterone) |
| Entry Date(s): | Date Created: 20231013 Date Completed: 20240109 Latest Revision: 20250104 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11135215 |
| DOI: | 10.1007/s00213-023-06471-y |
| PMID: | 37833541 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!